Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis

Cancer

Volumn 106, Issue 9, 2006, Pages 2021-2027

  Chamberlain, Marc C ^a   Tsao Wei, Denice D ^b   Groshen, Susan ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Etoposide; Intracerebrospinal; Neoplastic meningitis; Phase II trial; Toxicity

Indexed keywords

AMPHETAMINE DERIVATIVE; ANALGESIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; CARBOPLATIN; ETOPOSIDE; EXEMESTANE; GEFITINIB; GEMCITABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; METHOTREXATE; MODAFINIL; NAVELBINE; OXALIPLATIN; PSYCHOSTIMULANT AGENT; STEROID; TEMOZOLOMIDE; THALIDOMIDE; TRASTUZUMAB; VINCRISTINE;

ADULT; AGED; ARACHNOIDITIS; ARTICLE; BLOOD TOXICITY; BRAIN TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CEREBROSPINAL FLUID CYTOLOGY; CHEMICAL ARACHNOIDITIS; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; EVALUATION; FEMALE; HISTOLOGY; HUMAN; LUNG CANCER; MALE; MENINGITIS; NEOPLASTIC MENINGITIS; NEUROLOGIC EXAMINATION; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ETOPOSIDE; FEMALE; HUMANS; MALE; MENINGITIS; MIDDLE AGED; NEOPLASMS;

EID: 33646368162     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21828     Document Type: Article

References (25)

1. Balm M, Hammack J. Leptomeningeal carcinomatosis. Arch Neurol. 1996;53:626-632.
2. Grant R, Naylor B, Greenberg HS, et al. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol. 1994;51:457-461.
3. Grossman S, Moynihan T. Neurologic complications of systemic cancer: neoplastic meningitis. Neurol Clin. 1991;9:843-856.
4. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993;11:561-569.
5. Hitchens R, Bell D, Woods R, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987;5:1655-1662.
6. Glantz M, Jaeckle KA, Chamberlain MC, et al. A randomized trial of a slow-release formulation of cytarabine for the treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110-3116.
7. Glantz M, Jaeckle K, Chamberlain MC, et al. A randomized trial comparing intrathecal sustained-release ara-C (Depo-Cyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;11:3394-3402.
8. Chamberlain M, Dirr L. Involved field radiotherapy and intra-Ommaya methotrexate/ara-C in patients with AIDS-related lymphomatous meningitis. J Clin Oncol. 1993;11:1978-1984.
9. Fulton D, Levin V, Gutin P. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol. 1982;8:285-291.
10. Gutin P, Weiss H, Wiernik P, et al. Intrathecal N, N′, N″-triethylenethiophosphoramide [thio-TEPA (NSC 6369)] in the treatment of malignant meningeal disease. Phase I-II study. Cancer. 1976;38:1461-1465.
11. Shapiro W, Young D, Mehta B. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161-166.
12. Strong J, Collins J, Lester C, et al. Pharmacokinetics of intraventricular and intravenous N, N′, N″- triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res. 1986;46:6101-6104.
13. 111Indium-DTPA CSF flow studies. Neurology. 1991;41:1765-1769.
14. Glantz M, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow studies. Cancer. 1995;75:2919-2931.
15. Grossman S, Trump D, Chen D, et al. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. Ann J Med. 1982;73:621-627.
16. Lopez J, Nassif E, Vannicola P, et al. Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol. 1985;3:119-124.
17. Ackland S, Schilsky R. High-dose methotrexate: a critical reappraisal. J Oncol. 1987;5:2017-2031.
18. Slevin M, Piall E, Aderne G, et al. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol. 1983;1:546-551.
19. Savaraj N, Feun LG, Lu K, Gray K, Wang C, Loo TL. Pharmacology of intrathecal VP-16-213 in dogs. J Neurooncol. 1992;12:211-215.
20. van der Gaast A, Sonneveld P, Mans DR, Splinter TA. Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data. Cancer Chemother Pharmacol. 1992;29:335-337.
21. Fleischhack G, Reif S, Hasan C, Jaehde U, Hettmer S, Bode U. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer. 2001;84:1453-1459.
22. Slavc I, Schuller E, Falger J, et al. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J Neurooncol. 2003;64:239-247.
23. Slavc I, Schuller E, Falger J, et al. Tolerability of long-term intraventricular etoposide therapy with high cumulative doses in pediatric brain tumor patients [abstract]. Neurooncology. 2003;4:63.
24. Miller RG Jr. Kaplan-Meier curve for survival analysis, chapter 10. In: Miller RG Jr. Survival analysis. New York: John Wiley & Sons; 1981:114-118.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.